CGN Nuclear Technology Development Co (000881) Fair Value & Analysis

Industrials · CN · Market cap 6.7B CNY

Below-average quality, and screening another 74% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥2.30). The favourable scenario is already priced in.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
• A fairly wide model range (¥0.9700 to ¥2.30) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.

How to read this chart

60‑month range ¥5.00 – ¥13.87 · fair‑value band ¥0.9700 – ¥2.30 · the ¥6.43 price screens above the ¥1.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 25, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CGN Nuclear Technology Development Co (000881) currently trades at ¥6.43, while our model-based Fair Value estimate is ¥1.64, implying the stock looks roughly 74.5% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, CGN Nuclear Technology Development Co generated revenue of 5.6B CNY at a net margin of -5.0%. Revenue grew 1.8% year over year. It earns a return on equity of -5.6%. Net debt stands at 980M CNY. Fundamentals as of Jul 25, 2026

Our scenario range runs from ¥0.9700 (bear case) to ¥2.30 (bull case); at ¥6.43, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -14% fair-value upside, at -74%, 000881 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (¥3.68) versus Asset-Based (¥3.57). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

CGN Nuclear Technology Development Co., Ltd. manufactures and sells cable materials and industrial electron accelerators in China. It provides ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, and industrial flaw detection accelerators.

Full company description

CGN Nuclear Technology Development Co., Ltd. manufactures and sells cable materials and industrial electron accelerators in China. It provides ground nanoaccelerators, electronic curtain accelerators, DG resonant transformer accelerators, and industrial flaw detection accelerators. The company is also involved in the provision of electron beam treatment of specialty waste; antibiotic residue treatment technology; pharmaceutical wastewater treatment technology; medical sewage and solid waste disposal; park sewage treatment; printing and dyeing wastewater treatment technology; coal chemical coking wastewater treatment technology; chemical wastewater treatment technology; domestic sewage treatment technology; and hazardous waste concentrate treatment services. In addition, it provides new energy, irradiated, elastomer, and synthetic materials; modified polycarbonate and polyester, modified polypropylene, continuous fiber reinforced thermoplastic composites, and melt blown and radiation resistant polypropylene; and proton therapy tumor system equipment, raw materials and parts, radioactive medical isotopes, and hospital and nuclear drug products. Further, the company engages in production and sale of plastic; and real estate development, as well as contracting, irradiation processing, ocean shipping, maritime cargo transportation, ship investment and chartering, fishery, and project construction businesses. The company was formerly known as China Dalian International Cooperation (Group) Holdings Ltd. and changed its name to CGN Nuclear Technology Development Co., Ltd. in February 2017. CGN Nuclear Technology Development Co., Ltd. was founded in 1993 and is based in Shenzhen, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CGN Nuclear Technology Development Co reported revenue of ¥5.6B in FY2025 versus ¥8.0B in FY2021, a compound −8.7%/yr. Reported net income was −¥287M in FY2025.

000881 screens 74% overvalued. Compare with CITIC Limited →

Peer Group

Conglomerates · 370 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Conglomerates median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Insider activity: 51/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).

Explore undervalued stocks

More undervalued Industrials stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.